SARS-COV-2 drug repurposing - Caco2 cell line

ABSTRACT: To identify possible candidates for progression towards clinical studies against SARS-CoV-2, we screened a well-defined collection of 5632 compounds including 3488 compounds which have undergone clinical investigations (marketed drugs, phases 1 -3, and withdrawn) across 600 indications. Compounds were screened for their inhibition of viral induced cytotoxicity using the human epithelial colorectal adenocarcinoma cell line Caco-2 and a SARS-CoV-2 isolate. The primary screen of 5632 compounds gave 271 hits. A total of 64 compounds with IC50 <20 μM were identified, including 19 compounds with IC50 < 1 μM. Of this confirmed hit population, 90% have not yet been previously reported as active against SARS-CoV-2 in-vitro cell assays. Some 37 of the actives are launched drugs, 19 are in phases 1-3

ORGANISM(S): Homo sapiens

SUBMITTER: Bernhard Ellinger 

PROVIDER: S-BIAD29 | bioimages |

SECONDARY ACCESSION(S): http://idr.openmicroscopy.org/webclient/?show=screen-2603

REPOSITORIES: bioimages